Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

Opella is Sanofi’s consumer healthcare business unit focusing on ... Its portfolio primarily encompasses products related to Pain and inflammation, Digestive wellness, Allergy, Cough, cold ...

Sanofi gets rated buy today ... as it has been driving revenue from multiple products rather than a single magic drug.

for the potential sale of a 50% controlling stake in its consumer healthcare (CHC) business unit, Opella. Per the terms of the deal, Sanofi will remain a significant shareholder of Opella.

Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines.

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

Sanofi entered into exclusive talks to sell a controlling stake in its consumer-healthcare business Opella ... We sell different types of products and services to both investment professionals ...

The French government has taken a small stake in Sanofi's consumer healthcare business Opella, following political backlash about the pharmaceutical company's deal with a US private equity firm.

Together, CD&R and Sanofi will support Opella’s growth strategy as a pure-play, global, and fast-moving consumer healthcare company ... third parties nor do we endorse or guarantee their products. We ...